<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763226</url>
  </required_header>
  <id_info>
    <org_study_id>CV021-004</org_study_id>
    <nct_id>NCT04763226</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986308 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug&#xD;
      effects of BMS-986308 compared to placebo in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) leading to discontinuation</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Supine blood pressure</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Orthostatic hypotension measurements performed as per clinical research unit's standard operating procedure</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B&#xD;
PR interval is the time from the onset of the P wave to the start of the QRS complex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B&#xD;
QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B&#xD;
The QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B&#xD;
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in cardiac telemetry</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in physical examination findings</measure>
    <time_frame>Up to 19 days</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 72 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to 72 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events (AEs) leading to discontinuation</measure>
    <time_frame>Up to 72 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Supine blood pressure</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Orthostatic hypotension measurements performed as per clinical research unit's standard operating procedure</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A&#xD;
PR interval is the time from the onset of the P wave to the start of the QRS complex</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A&#xD;
QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A&#xD;
The QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A&#xD;
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in cardiac telemetry</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant changes in physical examination findings</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Part A</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part A Furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose (SAD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986308</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part B (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (for BMS-986308)</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part B (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A Furosemide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be in good health, as determined by no clinically significant deviations from&#xD;
             normal in medical history, physical examination, electrocardiograms (ECGs), and&#xD;
             clinical laboratory determinations&#xD;
&#xD;
          -  Must have a body mass index (BMI) of 18.0 kg/m^2 to 32.0 kg/m^2, inclusive, at&#xD;
             screening. BMI = weight (kg)/height (m)^2&#xD;
&#xD;
          -  Must have normal renal function at screening (and study admission) as evidenced by an&#xD;
             estimated glomerular filtration rate (eGFR) â‰¥ 80 mL/min/1.73 m^2 calculated with the&#xD;
             Chronic Kidney Disease Epidemiology Collaboration formula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Presence or need for urinary catheterization, urinary tract abnormality, or disorder&#xD;
             interfering with urination&#xD;
&#xD;
          -  History of tinnitus or hearing impairment, including deafness&#xD;
&#xD;
          -  History or risks factors for Torsade de Pointes and Long QT syndrome (such as&#xD;
             electrolyte imbalances, etc)&#xD;
&#xD;
          -  History of, or active, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             infection&#xD;
&#xD;
          -  Consumption of caffeine or xanthine-containing food or beverages within 72 hours prior&#xD;
             to study treatment administration&#xD;
&#xD;
          -  Use of any prescription drugs or over-the-counter (OTC) acid controllers within 4&#xD;
             weeks prior to study treatment administration except those medications cleared by the&#xD;
             Medical Monitor&#xD;
&#xD;
          -  Use of any other drugs, including OTC medications within 1 week and herbal&#xD;
             preparations, within 2 weeks prior to study treatment administration except those&#xD;
             medications cleared by the Medical Monitor&#xD;
&#xD;
          -  Use of diuretics (loop diuretics, thiazide diuretics, potassium-sparing diuretics&#xD;
             [spironolactone, amiloride]), oral calcium, potassium or magnesium supplements&#xD;
             (including multi-vitamins) or use of non-steroidal anti-inflammatory drugs within 72&#xD;
             hours of the first study treatment&#xD;
&#xD;
          -  Use of concomitant medications that are strong inhibitors or inducers of cytochrome&#xD;
             CYP3A4 or OATP administered within 2 weeks prior to study treatment administration and&#xD;
             throughout the study&#xD;
&#xD;
          -  Consumption of any nutrients known to modulate cytochrome P450 (CYP) enzymes activity&#xD;
             (eg, grapefruit, or grapefruit juice,pomelo juice, star fruit, or Seville [blood]&#xD;
             orange products) within 14 days prior to first administration of study treatment&#xD;
&#xD;
          -  Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs, ECG, or clinical laboratory determinations beyond&#xD;
             what is consistent with the target population of healthy volunteers&#xD;
&#xD;
          -  History of allergy to furosemide, sulfonamides, other loop diuretics (furosemide&#xD;
             cohort only), BMS-986308 or related compounds, components of the suspension or&#xD;
             solution, including hydroxypropylmethylcellulose&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PRA Health Sciences - Lenexa</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Dickerson, Site 0001</last_name>
      <phone>91341029739135992753</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-986308</keyword>
  <keyword>Congestive heart failure (CHF)</keyword>
  <keyword>Diuretics</keyword>
  <keyword>Diuretic resistance</keyword>
  <keyword>Fluid overload</keyword>
  <keyword>Furosemide</keyword>
  <keyword>Persistent congestion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

